Eledon Pharmaceuticals, Inc. announced the enrollment of the 12th participant on March 23, 2024, in the Company?s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.73 USD | +3.80% |
|
-9.90% | +51.67% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.67% | 105M | |
+15.19% | 121B | |
+19.91% | 114B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |
- Stock Market
- Equities
- ELDN Stock
- News Eledon Pharmaceuticals, Inc.
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection